Ajanta Pharma has soared 15% to Rs 1,124 after reporting over two-fold jump in standalone net profit at Rs 70 crore for the quarter ended March 31, 2014 (Q4FY14), on back of higher revenues from export. The pharmaceutical company had profit of Rs 27 crore in the same quarter year ago.
Revenue from operations grew 32% at Rs 311 crore during the quarter under review against Rs 249 crore in the corresponding quarter of previous fiscal. Exports contributed 66% of the total operating income for the quarter, Ajanta Pharma said in a statement.
Operational EBITDA (earnings before interest, taxes, depreciation and amortization) margins were reported at 36% in Q4FY14, higher than 27.7 in Q4FY13.
All our geographies have performed in line with our expectations. Our India specialty business continues to post robust growth much above the industry growth.
Meanwhile, the board has proposed dividend of 200% or Rs 10 per equity share of face value of Rs 5 each.
The stock opened at Rs 984 and hit a record high of Rs 1,140 on the NSE. The counter has seen over ten-fold jump in trading volumes with a combined 1.1 million shares changing hands so far on the NSE and BSE.
Revenue from operations grew 32% at Rs 311 crore during the quarter under review against Rs 249 crore in the corresponding quarter of previous fiscal. Exports contributed 66% of the total operating income for the quarter, Ajanta Pharma said in a statement.
Operational EBITDA (earnings before interest, taxes, depreciation and amortization) margins were reported at 36% in Q4FY14, higher than 27.7 in Q4FY13.
All our geographies have performed in line with our expectations. Our India specialty business continues to post robust growth much above the industry growth.
Meanwhile, the board has proposed dividend of 200% or Rs 10 per equity share of face value of Rs 5 each.
The stock opened at Rs 984 and hit a record high of Rs 1,140 on the NSE. The counter has seen over ten-fold jump in trading volumes with a combined 1.1 million shares changing hands so far on the NSE and BSE.
